GEOVAX LABS INC

GOVX14 Dec 2024
Healthcare
$2.35
-0.02 (-2.08%)
Lowest Today
$2.28
Highest Today
$2.39
Today’s Open
$2.35
Prev. Close
$2.4
52 Week High
$11.18
52 Week Low
$1.09
To Invest in GEOVAX LABS INC

GEOVAX LABS INC

Healthcare
GOVX14 Dec 2024
-0.02 (-2.08%)
1M
3M
6M
1Y
5Y
Low
$2.28
Day’s Range
High
$2.39
2.28
52 Week Low
$1.09
52-Week Range
52 Week High
$11.18
1.09
1 Day
-
1 Week
-9.07%
1 month return
-8.54%
3 month return
-14.36%
6 month return
+99.57%
1 Year return
-51.61%
3 Years return
-95.52%
5 Years return
-
10 Years return
-
Institutional Holdings
Renaissance Technologies Corp
2.82
Geode Capital Management, LLC
0.6
Fidelity Extended Market Index
0.31
BlackRock Inc
0.29
Two Sigma Investments LLC
0.24
Vanguard Group Inc
0.2
Vanguard Institutional Extnd Mkt Idx Tr
0.2

Market Status

Fundamentals
Market Cap
23.02 mln
PB Ratio
2.71
PE Ratio
0
Enterprise Value
21.6 mln
Total Assets
9.28 mln
Volume

Company Financials

Fund house & investment objective

Company Information
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Organisation
GEOVAX LABS INC
Employees
17
Industry
Biotechnology
CEO
Mr. David Alan Dodd
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities